Sofosbuvir: an all-around drug in hepatitis C treatment new era – The first phase

Alessia Ciancio

DOI: https://doi.org/10.7175/rhc.v6i2.1164

Abstract

Chronic hepatitis C virus (HCV) infection is a slowly progressive disease affecting more than 185 million people worldwide. For many years, the combination of pegylated interferon (Peg-IFN) plus ribavirin (RBV) has been the backbone of treatment for patients infected with HCV. More than two years ago, the first generation direct-acting antiviral agents (DAAs) – the protease inhibitors boceprevir and telaprevir – were approved for treatment of genotype 1 patients, doubling the cure rate. The new DAAs that have been developed, are effective for multiple genotypes, improve rates of sustained viral response with fewer side effects, simplify dosing and drug-drug interactions, and in some patients, offer the promise of interferon-free and/or ribavirin-free therapy. These new agents include the recently approved second generation protease inhibitor, the HCV NS5B polymerase inhibitor sofosbuvir and the NS3/4A protease inhibitor simeprevir as well as several other agents that are currently in later phases of development. With sofosbuvir-based regimens, successful interferon-free treatment is now available across all genotypes. In fact sofosbuvir is very effective in combination with Peg-interferon and ribavirine or with ribavirine alone or with other direct anti-viral agents. The following assessment evaluates the evidence on the clinical effectiveness and harms of sofosbuvir for the treatment of chronic hepatitis C.

Keywords

Chronic hepatitis C virus; Sofosbuvir; Protease inhibitor

Full Text

HTML PDF

References

  • Sovaldi™ – Riassunto delle Caratteristiche di Prodotto
  • Cornpropst M, Denning J, Clemons D, et al. The effect of renal impairment and end stage renal disease on the single-dose pharmacokinetics of PSI-7977. 47th Annual Meeting of the European Association for the Study of the Liver (EASL). Barcelona, 2012
  • Gane EJ, Robson RA, Bonacini M, et al. Safety, Anti-Viral Efficacy and Pharmacokinetics (PK) of Sofosbuvir (SOF) in Patients with Severe Renal Impairment. 65th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD). Boston, 2014
  • Lawitz E, Rodriguez-Torrez M, Cornpropst M, et al. The effect of hepatic impairment on the pharmacokinetics and antiviral activity of PSI-7977 in hepatitis C infected subjects treated for seven days. 47th Annual Meeting of the European Association for the Study of the Liver (EASL). Barcelona, 2012
  • Mathias A, Cornpropst M, Clemons D, et al. No clinically significant pharmacokinetic drug-drug interactions between sofosbuvir (GS-7977) and the immunosuppressants, cyclosporine A or tacrolimus in healthy volunteers. 63rd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD). Boston, 2012
  • Denning J, Cornpropst M, Clemons D, et al. Lack of effect of the nucleoside analog polymerase inhibitor PSI-7977 on methadone PK and PD. 62nd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD). San Francisco, 2011
  • Gane E, Stedman C, Hyland R, et al. Once daily sofosbuvir (GS-7977) plus ribavirin in patients with HCV genotypes 1, 2, and 3: the ELECTRON trial. 65th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD). Boston, 2014
  • Rodriguez-Torres M, Lawitz E Kowdley K, et al. Sofosbuvir (GS-7977) plus peginterferon/ribavirin in treatment-naive patients with HCV genotype 1: A randomized, 28-day, dose-ranging trial. J Hepatol 2013; 58: 663-8; http://dx.doi.org/10.1016/j.jhep.2012.11.018
  • Lawitz E, Lalezari J, Hassanein T, et al. Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial. Lancet Infect Dis 2013; 13: 401-8; http://dx.doi.org/10.1016/S1473-3099(13)70033-1
  • Gane E, Stedman C, Hyland R, et al. Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. N Engl J Med 2013; 368: 34-44; http://dx.doi.org/10.1056/NEJMoa1208953
  • Kowdley K, Lawitz E, Crespo I, et al. Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial. Lancet 2013; 381: 2100-7; http://dx.doi.org/10.1016/S0140-6736(13)60247-0
  • Lawitz E, Mangia A, Wyles D, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013; 368:1878-87; http://dx.doi.org/10.1056/NEJMoa1214853
  • Jacobson I, Gordon S, Kowdley K, et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med 2013; 368: 1867-77; http://dx.doi.org/10.1056/NEJMoa1214854
  • Zeuzem S, Dusheiko GM, Salupere R, et al. Sofosbuvir and ribavirin in HCV genotypes 2 and 3. N Engl J Med 2014; 370: 1993-2001; http://dx.doi.org/10.1056/NEJMoa1316145
  • Lawitz E, Poordad F, Brainard DM, et al. Sofosbuvir in Combination With PegIFN and Ribavirin for 12 Weeks Provides High SVR Rates in HCV-Infected Genotype 2 or 3 Treatment Experienced Patients with and without Compensated Cirrhosis: Results from the LONESTAR-2 Study. 64th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD). Washington, DC, 2013
  • Ruane PJ1, Ain D2, Stryker R, et al. Sofosbuvir plus ribavirin for the treatment of chronic genotype 4 hepatitis C virus infection in patients of Egyptian ancestry. J Hepatol 2014 [Epub ahead of print]; http://dx.doi.org/10.1016/j.jhep.2014.10.044
  • Curry MP, Forns X, Chung RT, et al. Sofosbuvir and ribavirin prevent recurrence of HCV infection after liver transplantation: an open-label study. Gastroenterology 2015; 148: 100-7; http://dx.doi.org/10.1053/j.gastro.2014.09.023
  • Samuel, M Charlton, E Gane, et al. Sofosbuvir and ribavirin for the treatment of recurrent hepatitis C infection after liver transplantation: results of a prospective, multicenter study. 49th Annual Meeting of the European Association for the Study of the Liver (EASL). London, 2014
  • Lawitz E, Sulkowski MS, Ghalib R, et al. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study. Lancet 2014; 384: 1756-65; http://dx.doi.org/10.1016/S0140-6736(14)61036-9
  • Aqel B, Pungpapong S, Werne KTr, et al. The use of simeprevir and sofosbuvir to treat HCV G1 in the Liver Transplant Setting: The experience in 3 US Centers. 65th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD). Boston, 2014
  • Pungpapong S, Werner KT, Aqel B, et al. Multicenter Experience using Sofosbuvir and Simeprevir with/without Ribavirin to Treat HCV Genotype 1 after Liver Transplantation. 65th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD). Boston, 2014
  • Jensen DM, O’Leary JG, Pockros PJ, et al. Safety and Efficacy of Sofosbuvir-Containing Regimens for Hepatitis C: Real-World Experience in a Diverse, Longitudinal Observational Cohort. 65th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD). Boston, 2014
  • Dieterich D, Bacon BR, Flamm SL, et al. Evaluation of sofosbuvir and simeprevir-based regimens in the TRIO network: academic and community treatment of a real-world, heterogeneous population. 65th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD). Boston, 2014

Statistics

Abstract: 1132 views
HTML: 1116 views
PDF: 311 views

Refbacks

  • There are currently no refbacks.